Jones Frank, Hu Yanmin, Coates Anthony
Institute for Infection and Immunity, St George's University of London, London SW17 0RE, UK.
Antibiotics (Basel). 2022 Feb 28;11(3):323. doi: 10.3390/antibiotics11030323.
is a Gram-negative bacterium which is capable of developing a high level of antibiotic resistance. It has been placed on the WHO's critical priority pathogen list and it is commonly found in ventilator-associated pneumonia infections, blood stream infections and other largely hospital-acquired illnesses. These infections are difficult to effectively treat due to their increasing antibiotic resistance and as such patients are often treated with antibiotic combination regimens.
We conducted a systematic search with screening criteria using the Ovid search engine and the Embase, Ovid Medline, and APA PsycInfo databases.
It was found that in many cases the combination therapies were able to match or outperform the monotherapies and none performed noticeably worse than the monotherapies. However, the clinical studies were mostly small, only a few were prospective randomized clinical trials and statistical significance was lacking.
It was concluded that combination therapies have a place in the treatment of these highly resistant bacteria and, in some cases, there is some evidence to suggest that they provide a more effective treatment than monotherapies.
是一种革兰氏阴性菌,能够产生高水平的抗生素耐药性。它已被列入世界卫生组织的关键优先病原体名单,常见于呼吸机相关性肺炎感染、血流感染和其他主要的医院获得性疾病中。由于这些感染的抗生素耐药性不断增加,难以有效治疗,因此患者通常采用联合抗生素治疗方案。
我们使用Ovid搜索引擎以及Embase、Ovid Medline和APA PsycInfo数据库,根据筛选标准进行了系统检索。
发现许多情况下联合疗法能够与单一疗法相当或优于单一疗法,且没有一种联合疗法明显比单一疗法差。然而,临床研究大多规模较小,只有少数是前瞻性随机临床试验,缺乏统计学意义。
得出的结论是联合疗法在治疗这些高度耐药细菌方面有一席之地,在某些情况下,有证据表明它们比单一疗法提供更有效的治疗。